Biotech: Page 23
-
Courtesy of BioMarin Pharmaceutical
BioMarin to lay off over 200 employees
The company has reshuffled its executive team, cut back spending and trimmed its drug pipeline this year, changes aimed at refocusing its resources.
By Delilah Alvarado • Aug. 29, 2024 -
Getty Images
Cell and gene therapy investment, once booming, is now in a slump
Far fewer venture funding rounds were closed by cell and gene therapy developers over the first six months of 2024 than in prior years. Experts say there are several factors.
By Gwendolyn Wu • Aug. 29, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Sean Gallup via Getty Images
Bayer partners with RNA drugmaker to develop new cancer therapies
Under a collaboration with NextRNA Therapeutics, Bayer will access the biotech’s platform to target long, non-coding RNA interactions with small molecule drugs.
By Delilah Alvarado • Aug. 28, 2024 -
Getty Images
RA Capital-backed startup raises $100M; UCB sells China business
New biotech Navigator is working on drugs for immune diseases. Meanwhile, UCB sold its neurology and allergy business in China, and J&J's Peter Fasolo will retire this year.
By BioPharma Dive staff • Aug. 27, 2024 -
Getty Images
Tome Biosciences to lay off over 100 employees
The buzzy startup, which had raised over $200 million in venture funding, is letting go of much of its workforce, according to a state regulatory notice.
By Delilah Alvarado • Aug. 26, 2024 -
Permission granted by Versant Ventures
Q&A // Emerging biotechVersant’s Jerel Davis on build-to-buy deals and pharma investment
Build-to-buy arrangements can give pharmaceutical companies an option to acquire a startup’s assets later, as with Novartis’ deal with the Versant-backed Borealis Biosciences.
By Gwendolyn Wu • Aug. 26, 2024 -
Permission granted by Menarini Silicon Biosystems
Sponsored by Menarini Silicon BiosystemsA truly comprehensive liquid biopsy approach: DLL3 and the rise of customized CTC and cfDNA/cfRNA analysis with CellSearch® and MenariniSearch
Imagine the power of combining CTCs, cell-free DNA and cell-free RNA.
Aug. 26, 2024 -
Getty Images
Sponsored by AltasciencesHow biotech companies and CROs can better align to accelerate development for the most promising discoveries
CROs are vital in supporting biotech with R&D. How can that relationship go from transactional to partnership?
Aug. 26, 2024 -
Michael M. Santiago via Getty Images
Two antibody startups file for IPOs amid summer slump
Armed with clinical-stage data, Zenas BioPharma and Bicara Therapeutics both fit the profile of biotechs that have successfully pulled off IPOs this year.
By Gwendolyn Wu • Aug. 23, 2024 -
Getty Images
FDA to convene immunotherapy panel; Tome scales back operations
Agency advisers will discuss whether use of Keytruda and Opdivo should be limited in gastric cancer. Elsewhere, a buzzy genetic drug startup is exploring “strategic options.”
By BioPharma Dive staff • Aug. 23, 2024 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
Updated COVID shots from Pfizer, Moderna cleared by FDA
Approval of the reformulated mRNA vaccines, which are designed to target the KP.2 virus strain, comes just ahead of the fall and winter seasons.
By Ned Pagliarulo • Aug. 22, 2024 -
Courtesy of Novartis
Versant reimagines its Chinook success with newest startup launch
Borealis Biosciences launches with money from Novartis, which last year bought the biotech’s predecessor for drugs that treat a rare kidney disorder.
By Gwendolyn Wu • Aug. 22, 2024 -
Getty Images
BridgeBio sends rare disease drugs to new company
Backed by $300 million from investors that include Viking Global Investors and Sequoia Capital, GondolaBio will inherit several BridgeBio drug programs.
By Ned Pagliarulo • Aug. 21, 2024 -
Courtesy of BioMarin Pharmaceutical
BioMarin taps Amgen, Roche vets in executive reshuffle
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
By Jacob Bell • Aug. 21, 2024 -
Getty Images
Avidity, Kymera raise fresh funds; Walgreens partners with BARDA
Avidity raised $345 million to advance development of RNA medicines designed to combine the advantages of oligonucleotides and antibodies.
By BioPharma Dive staff • Aug. 20, 2024 -
Getty Images
Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance
Zealand is using a recent $1 billion equity raise to “accelerate” several would-be weight loss medicines. Meanwhile, Bluebird reworked a loan and Boundless Bio cut jobs only months after an IPO.
By BioPharma Dive staff • Aug. 16, 2024 -
Getty Images
Lykos to cut 75% of staff after FDA rejection of MDMA-based therapy
The layoffs are part of a larger reorganization that will also see the departure of Lykos’ founder, the psychedelics advocate Rick Doblin.
By Jacob Bell • Aug. 15, 2024 -
Courtesy of Grail
Grail to shed 350 workers in restructuring
Less than two months after splitting from Illumina, the liquid biopsy maker is refocusing resources as it pursues an FDA submission for the Galleri multi-cancer early detection test.
By Susan Kelly • Aug. 14, 2024 -
Getty Images
Acelyrin shifts from main drug, lays off staff
The company will no longer develop its medicine izokibep in two immune conditions, prioritizing another treatment it’s developing for thyroid eye disease.
By Ned Pagliarulo • Aug. 13, 2024 -
Sarah Silbiger via Getty Images
Galderma wins FDA approval for skin condition treatment
Nemluvio is now cleared for adults with the chronic itching condition prurigo nodularis, making it a competitor to Sanofi and Regeneron’s Dupixent.
By Ned Pagliarulo • Updated Aug. 13, 2024 -
Getty Images
Lilly opens R&D hub; Ovid and Lexicon lay off staff
Lilly’s new center in Boston will focus on genetic medicine research and provide lab space for startups. Elsewhere, two biotechs cut jobs and two others advanced psychedelic medicines.
By BioPharma Dive staff • Aug. 13, 2024 -
Getty Images
Startup Halda raises $126M to advance new type of targeted cancer therapy
Technology inspired by work at Yale researcher Craig Crews’ labs will be used to target prostate and breast cancer in early clinical trials.
By Jonathan Gardner • Updated Aug. 13, 2024 -
Sarah Silbiger via Getty Images
FDA approves Ascendis drug for rare endocrine condition
The clearance of Yorvipath for hypoparathyroidism was some time coming for Ascendis, which had resubmitted after receiving a rejection last year.
By Ned Pagliarulo • Aug. 12, 2024 -
Getty Images
Emerging biotechWith pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
Recent data from J.P. Morgan indicates early-stage startups are getting smaller upfront payments in alliances than a few years ago, a trend industry insiders attribute to weaker leverage in deal talks.
By Gwendolyn Wu • Aug. 9, 2024 -
Getty Images
Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study
Merck stopped a Phase 3 TIGIT study for futility. Elsewhere, shares in Cabaletta Bio sank on safety worries and Vertex secured Casgevy reimbursement in England.
By BioPharma Dive staff • Aug. 8, 2024
Previous
